Immune thrombocytopenia: No longer ‘idiopathic’
- 1 June 2011
- journal article
- review article
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 78 (6), 358-373
- https://doi.org/10.3949/ccjm.78gr.10005
Abstract
Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.Keywords
This publication has 43 references indexed in Scilit:
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseHaematologica, 2010
- The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature reviewEuropean Journal of Haematology, 2009
- Molecular mimicry and immune thrombocytopeniaBlood, 2009
- Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C–related immunologic thrombocytopeniaBlood, 2009
- Fc receptors in immune thrombocytopenias: a target for immunomodulation?JCI Insight, 2008
- Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline ThrombocytopeniaPLoS Medicine, 2006
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans SyndromeMayo Clinic Proceedings, 2003
- Hepatitis C virus infection and autoimmune thrombocytopenic purpuraJournal of Hepatology, 1995